By Katherine Hamilton

Citius Oncology shares climbed after the company commercially launched its treatment Lymphir for patients with a rare type of cancer that affects the skin.

The stock rose 14.5% to $1.57 on Monday. Shares have gained 37% this year.

Lymphir, which is approved by the Food and Drug Administration to treat adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma, will now be available throughout the U.S., the Cranford, N.J., company said Monday.

A phase 3 trial demonstrated an objective response rate of 36%, with 84% of evaluable patients experiencing a reduction in skin tumor burden, Citius said. The median time to response was 1.4 months.

Lymphir may offer rapid skin relief to patients experiencing itching, which is common with lymphoma, the company said.

Outside the U.S., Citius holds exclusive rights to develop and commercialize Lymphir in all global markets except India, Japan and certain parts of Asia.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 01, 2025 12:43 ET (17:43 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.